• Human LILRB5/CD85c/LIR-8 protein (Recombinant) (C-His-Avi) {Biotin} (STJP001745)
  • Human LILRB5/CD85c/LIR-8 protein (Recombinant) (C-His-Avi) {Biotin} (STJP001745)

Human LILRB5/CD85c/LIR-8 protein (Recombinant) (C-His-Avi) {Biotin} (STJP001745)

SKU:
STJP001745

Shipping:
Free Shipping
Current Stock:
Host: HEK293
Note: STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human LILRB5/CD85c/LIR-8-C-His-Avi protein was developed from hek293 and has a target region of C-His-Avi. For use in research applications.
Conjugation: Biotin
Formulation: Lyophilised from 0.2 µm filtered PBS solution pH7.4.
Dilution Range: Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM
Storage Instruction: The lyophilized protein is stable for at least 1 year from date of receipt at-20°C.
Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg).
Gene Symbol: LILRB5
Gene ID: 10990
Uniprot ID: LIRB5_HUMAN
Immunogen Region: Arg18-His456
Immunogen: DNA sequence encoding Human LILRB5/CD85c/LIR-8 including a C-His-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology.
Function May act as receptor for class I MHC antigens.
Protein Name Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 5
Cd85 Antigen-Like Family Member C
Leukocyte Immunoglobulin-Like Receptor 8
Lir-8
Cd Antigen Cd85c
Database Links Reactome: R-HSA-198933
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Protein Names Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 5 protein
Cd85 Antigen-Like Family Member C protein
Leukocyte Immunoglobulin-Like Receptor 8 protein
Lir-8 protein
Cd Antigen Cd85c protein
LILRB5 protein
LIR8 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance